Reported 2 months ago
According to a bullish analyst at Barclays, Abbott Laboratories (NYSE: ABT) stock has the potential to rise to $143, presenting an attractive opportunity for investors at its current price of around $108. Despite a recent court ruling involving a baby formula lawsuit, Abbott’s strong earnings, innovative medical devices, and consistent dividend growth may support this optimistic outlook. However, potential investors should also weigh the risks posed by ongoing legal issues against the company's robust sales growth and market position.
Source: YAHOO